+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 8 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating the effects of experimental drugs pozelimab and cemdisiran in adults aged 50 to 85 with Geographic Atrophy GA caused by Age-related Macular Degeneration AMD, a condition affecting central vision. The study aims to compare the progression rate of GA in patients treated with cemdisiran alone, pozelimab combined with cemdisiran, and a placebo, while also examining side effects, drug levels in the blood, and immune responses to the drugs. Participants are randomly assigned to one of three groups pozelimab plus cemdisiran, cemdisiran alone, or placebo. All treatments are given by subcutaneous injection. The study is double-masked and placebo-controlled, lasting up to 104 weeks for key outcome measures, with extended safety monitoring up to 296 weeks. The trial includes multiple visits for evaluations and treatments over this period. During the study, participants undergo detailed eye imaging using Fundus Autofluorescence to measure GA lesion growth, assessments of visual acuity, and contrast sensitivity tests at weeks 52 and 104. Blood samples are collected to measure drug concentrations and immune responses, including antibodies against the drugs. Safety is monitored throughout the study and during extended follow-up. Participants adherence to clinic visits and vaccinations is required for participation.

Age: 50Years - 85YearsAll GendersPhase 3
231 locations
S

Actively Recruiting

Researchers are studying how certain factors like age, gender, other medical conditions, and the type of immunotherapy affect whether patients with malignant solid tumors develop mild or serious side effects from immune checkpoint inhibitor treatments. This observational study aims to develop and validate a model that predicts severe immune-related side effects during the first year of immunotherapy, while also assessing quality of life and adverse events over 12 months. The study is sponsored by the SWOG Cancer Research Network and includes translational medicine goals such as evaluating cytokine levels as predictors and establishing a tissue and blood sample repository. Participants will provide a tissue sample at the start of their routine cancer treatment and complete questionnaires at multiple time points at treatment start, and weeks 4, 12, 24, and 52. They may also provide optional blood samples during the study. This design allows researchers to monitor immune-related side effects and patient-reported outcomes over time. During the study, participants will complete various questionnaires to report their quality of life, cognitive function, and side effects. Blood and tissue samples will be analyzed to explore predictive markers of toxicity. Researchers will track the occurrence of severe immune-related side effects over 52 weeks and assess changes in patient-reported outcomes. The study includes ongoing monitoring and data collection, with participation lasting approximately one year from treatment start.

Age: 18Years +All Genders
849 locations
T

Actively Recruiting

Researchers are evaluating a text-based smoking cessation program for rural cancer survivors who smoke. This phase III trial compares an eight-week scheduled gradual reduction program paired with supportive text messages to a control intervention using an informational booklet. The study aims to assess which method better helps these patients quit smoking, with a focus on improving quality of life. The trial targets adults diagnosed with cancer within the past 10 years who currently smoke at least five cigarettes daily and live in rural areas. Participants are randomly assigned to one of two groups. One group follows a personalized eight-week gradual reduction schedule for smoking, supported by 12 weeks of cessation text messages. The other group receives the National Cancer Institutes Clearing the Air booklet to assist with quitting plans. Both groups are followed for six months after their quit date to evaluate outcomes. During the study, participants complete assessments including biochemical validation of smoking cessation up to six months post-quit date. Quality of life is measured at baseline, 30 days, and six months after quitting. Participants provide urine samples and must have texting capability on a phone to receive intervention messages. Safety and progress are monitored throughout, with the total participation lasting up to six months post-quit date.

Age: 18Years +All GendersPhase 3
224 locations
T

Actively Recruiting

Researchers are evaluating targeted cancer treatments directed by genetic testing for patients with locally advanced or advanced solid tumors. This ComboMATCH patient screening trial is designed to match patients with specific genetic mutations in their tumor cells to investigational combination therapies. Patients included have tumors that have spread or progressed after standard treatments, or have no standard treatment proven to extend survival. The study aims to improve treatment planning by using genetic information to assign therapies. Participants undergo tumor mutational screening using previously collected tumor samples. Eligible patients aged 18 and older with biopsiable disease may have a new biopsy before starting treatment. Those with relevant mutations are assigned to one of 20 treatment subprotocols involving various drug combinations and regimens, including oral, intravenous, and intramuscular administration. Treatments are given in repeated 28-day cycles, continuing without disease progression or unacceptable toxicity. The trial includes multiple arms and cohorts tailored to specific genetic alterations and cancer types, with some allowing crossover if disease progresses. Throughout the study, participants have tumor biopsies, blood collections, imaging tests such as CT, MRI, PET scans, and cardiac assessments like echocardiograms or MUGA scans. Bone marrow aspirations or biopsies, bone scans, and brain imaging may also be performed as clinically indicated. Researchers measure patient enrollment and treatment assignment, as well as positive treatment outcomes in defined molecular cohorts. The trial may last up to 8 years, with ongoing monitoring and optional additional biopsies at disease progression to assess treatment effects and safety.

All AgesAll GendersPhase 2
484 locations
E

Actively Recruiting

Researchers are comparing early versus delayed treatment using venetoclax and obinutuzumab in patients newly diagnosed with high-risk chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL. This phase III trial aims to see if starting treatment before symptoms appear improves overall survival and other outcomes. Venetoclax is a BCL-2 inhibitor that may stop cancer cell growth, and obinutuzumab is a monoclonal antibody that may help the immune system attack cancer cells. Participants are randomly assigned to one of two groups one begins treatment early after meeting eligibility criteria, and the other starts treatment only after symptoms develop. Both groups receive obinutuzumab intravenously on specified days during the first six cycles and venetoclax orally daily during later cycles, with treatment repeated every 28 days for up to 12 cycles. During and after treatment, patients undergo CT scans, blood sample collections, and bone marrow biopsies. Participants are monitored for up to 10 years after treatment to assess overall survival, progression-free survival, response rates, safety, and quality of life using the FACT-Leukemia scale. Researchers collect various samples and data, including measurable residual disease status and biomarkers. Patient compliance and adverse events are also tracked to better understand the treatment effects and long-term outcomes.

Age: 18Years +All GendersPhase 3
633 locations
E

Actively Recruiting

Researchers are evaluating the addition of pembrolizumab, a type of immunotherapy, to standard chemotherapy for patients with stage IIA, IIB, IIIA, or IIIB non-small cell lung cancer NSCLC that has been completely removed by surgery. This phase III trial aims to compare disease-free survival and overall survival between different treatment approaches, including chemotherapy alone and chemotherapy combined with pembrolizumab. The study also investigates side effects, drug discontinuation rates, quality of life, and specific biomarkers such as PD-L1 expression and tumor mutational burden. Participants are randomly assigned to one of two treatment groups. Both groups initially receive one of four chemotherapy regimens every 21 days for four cycles, chosen by their doctor. In one group, pembrolizumab is given after chemotherapy as an intravenous infusion every 21 days for up to 17 cycles or every 6 weeks for up to 16 cycles. In the other group, pembrolizumab is given together with chemotherapy during the initial cycles and then continued as monotherapy. Patients undergo various scans and blood tests throughout the study, including echocardiograms, MRIs, CT scans, and blood sample collections. During the trial, participants are closely monitored for disease status and side effects. Follow-up visits occur six weeks after treatment, then every three months for two years, every six months for years two to four, and annually for up to ten years after randomization. Quality of life questionnaires and symptom assessments are also completed. The main measure of success is disease-free survival, tracked for up to five years after enrollment. Safety and overall survival are reviewed for up to ten years to ensure long-term monitoring.

Age: 18Years +All GendersPhase 3
1151 locations
R

Actively Recruiting

Researchers are evaluating the effects of neratinib alone versus a combination of neratinib and palbociclib in patients with HER2 positive solid tumors, including gynecologic cancers. This Phase II trial aims to compare the progression-free survival between these treatments, as both drugs belong to a class called kinase inhibitors that block cancer cell growth signals. The study also explores additional outcomes such as response rates, overall survival, and side effects. Participants are randomly assigned to one of two treatment groups. One group receives neratinib orally daily on specific days of each 28-day cycle, with the possibility to switch to the combination treatment if their disease progresses. The second group receives both neratinib and palbociclib with defined daily dosing schedules within each cycle. During the trial, patients undergo various scans including echocardiograms, CT or MRI scans, and blood sample collections. Tumor biopsies may also be performed before and during treatment. After finishing the study treatments, patients are followed every three months for two years. Throughout the study, participants will have regular assessments to monitor their cancer status and therapy effects. This includes imaging to evaluate tumor response, blood tests to collect biological samples, and cardiac function evaluations. Researchers will measure progression-free survival as the primary outcome and overall survival as a secondary outcome. Safety will be monitored by tracking adverse events, especially serious toxicities. The total participation time includes treatment cycles and a two-year follow-up period to observe long-term outcomes.

Age: 18Years +All GendersPhase 2
194 locations
H

Actively Recruiting

Researchers are studying whether high-dose vitamin D can help prevent bone loss caused by androgen-deprivation therapy ADT in men with prostate cancer. This phase III trial focuses on men aged 50 and older who are undergoing ADT, which can weaken bones. Vitamin D helps the body absorb calcium, essential for strong bones, and the study aims to see if high doses of vitamin D can keep bones strong, reduce falls, and lessen fatigue in these patients. Participants are randomly assigned to one of two groups. One group receives high-dose vitamin D orally once a week for 52 weeks, while the other group receives a placebo on the same schedule. Both groups undergo blood collection and bone density scans during the study to monitor changes in bone health. Throughout the 52 weeks, participants will have bone density measured at multiple sites using dual-energy x-ray absorptiometry DXA, and researchers will track falls, fractures, quality of life, pain, fatigue, sleep, and daily activities through questionnaires and clinical records. The study includes regular assessments of blood vitamin D and calcium levels to ensure safety and effectiveness of the supplementation.

Age: 50Years +MALEPhase 3
51 locations